Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  wild-type reovirus
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-15 of 15 for your search:
Start Over
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 018, NCT01166542
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 014, NCT00503295
Viral Therapy in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00233, MAYO-MC0672, 7848, CDR0000592801, MC0672, N01CM00070, NCT00651157
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 015, NCT00753038
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 016, NCT00861627
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 020, NCT00984464
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 021, NCT00998192
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 017, NCT00998322
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02654, CDR0000684693, GOG-0186H, U10CA180868, U10CA027469, NCT01199263
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02567, OSU-10045, CDR0000692060, 8601, N01CM00070, N01CM62207, P30CA016058, NCT01280058
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: I210, NCT01622543
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 007, NCT00528684
Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00234, CDR0000584038, OSU-07022, 2007C0028, 07022, 7853, P30CA016058, U01CA076576, NCT00602277
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 3 to 21
Sponsor: NCI
Protocol IDs: NCI-2011-02617, CDR0000688938, ADVL1014, U01CA097452, COG-ADVL1014, NCT01240538
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00248, CDR0000724857, 2011C0141, 9030, OSU 11148, P30CA016058, U01CA076576, 11148, NCT01533194
Start Over